Contineum Therapeutics, Inc.
CTNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855175
In the last 90 days, Contineum Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $500.6M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $248.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $41.1K in total
- 1
- 13F holdersQ2 2026, +14 vs. previous quarter
- 102
- 13F valueReported value at the end of Q2 2026
- $500.6M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$60.0M
- No comparable prior period
- Free cash flow, FY2025
- -$55.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.70M
- Shares sold short
- Change
- +41.4K
- +1.1% vs. previous
- Days to cover
- 4.23
- At average daily volume
Superinvestors holding CTNM, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Contineum Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.3%
Contineum Therapeutics, Inc.'s share of the portfolio
- Shares
- 669,337
- Value
- $11.0M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Contineum Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)6:08 PM ET | Sep 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.46 | −$41.1K | −12.7%17.2K after | 10b5-1 |
| Aug 3, 2026 (view filing)6:14 PM ET | Aug 3 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.01 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 10, 2026 (view filing)5:20 PM ET | Jul 8-9 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −1.04K | $16.00 | −$16.6K | −0.8%135.2K after | 2 lots10b5-1 |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.00 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)5:47 PM ET | Jun 30-Jul 1 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −37.2K | $15.99 | −$594.6K | −21.6%135.2K after | 3 lots10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −10.8K | $16.02 | −$173.6K | −54.7%8.96K after | 10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −10.0K | $16.01 | −$160.1K | −36.7%17.2K after | 10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.16 | −$54.9K | −2.9%139.4K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.12 | −$54.7K | −2.8%143.5K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 6 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.43 | −$56.0K | −2.7%147.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 102 holdersThe largest institutional positions in Contineum Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,841,334 | $46.6M | 0.98% | 00.0% | Unchanged |
| Jupiter Topco LLC | 2,734,836 | $44.8M | 0.02% | +2,734,836 | New |
| BlackRock, Inc. | 2,064,345 | $33.8M | 0.00% | +1,395,222+208.5% | Added |
| Johnson & Johnson | 1,979,173 | $32.4M | 4.06% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,839,227 | $30.1M | 0.01% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 1,522,793 | $25.0M | 0.05% | −162,842−9.7% | Reduced |
| Vanguard Capital Management LLC | 1,321,356 | $21.7M | 0.00% | +107,183+8.8% | Added |
| Perceptive Advisors LLC | 1,255,592 | $20.6M | 0.32% | 00.0% | Unchanged |
| FMR LLC | 1,040,130 | $17.0M | 0.00% | +225,259+27.6% | Added |
| Millennium Management LLC | 931,709 | $15.3M | 0.01% | −603,740−39.3% | Reduced |
Holders of 5% or more of CTNM
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Contineum Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G | 7.90%2.61M shares | New | Nov 5, 20261 filing | Nov 5, 2026 | SEC |
| Janus Henderson Group PLC | 13G | 7.90%2.45M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Balyasny Asset Management LLC | 13G/A | 7.14%2.34M shares | −0.26 ppfrom 7.40% | Feb 17, 20263 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.30%2.05M shares | New | Jul 27, 20261 filing | Jul 27, 2026 | SEC |
| Johnson & Johnson Innovation - JJDC, Inc. | 13G/A | 5.60%1.98M shares | – | Nov 6, 20261 filing | Nov 6, 2026 | SEC |